Mallinckrodt Plc Ordinary Share (MNK) 79.66 $MNK Gilead

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mallinckrodt Plc Ordinary Share (MNK) 79.66 $MNK

Gilead Sciences, Williams Companies, Procter & Gamble, Mallinckrodt Public Limited Company, and Western Digital and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, MNK, PG, WDC, and WMB.
MNK: 79.66 (+2.75), GILD: 80.09 (+0.52), WMB: 25.67 (+1.71), PG: 85.97 (-0.79), WDC: 44.78 (-0.27)

Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 79.66 (+2.75), IPXL: 31.62 (+0.65), SUPN: 22.92 (+0.66), MYL: 48.41 (+1.88)

Royal Caribbean and General Motors fall; CVS advances
AP - Tue Aug 02, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MNK: 79.66 (+2.75), DISCK: 25.91 (+0.50), F: 12.13 (+0.19), DAL: 36.48 (+0.09), PFE: 35.29 (-1.10), STX: 30.73 (+0.08), DISCB: 25.82 (-0.03), DISCA: 26.83 (+0.41), CVS: 97.43 (-0.63), GM: 30.24 (+0.31)

Mallinckrodt (MNK) Tops on Earnings & Sales in Q3
Ekta Bagri - Zacks Investment Research - Tue Aug 02, 5:48AM CDT
Mallinckrodt beat on earnings by a wide margin. Our consensus called for EPS of $2.01, and the company reported EPS of $2.20.
MNK: 79.66 (+2.75)

Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016
PR Newswire - Tue Aug 02, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 20161. Unless otherwise noted, all comparisons of fiscal 2016 third quarter or year-to-date performance are to the comparable periods of fiscal 2015.
MNK: 79.66 (+2.75)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)

First Patient Enrolled in Mallinckrodt Phase 3 Terlipressin Trial
PR Newswire - Thu Jul 28, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 3 clinical study to evaluate the efficacy and safety of terlipressin (for injection) in subjects with Hepatorenal Syndrome (HRS) type 1.
MNK: 79.66 (+2.75)

Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 79.66 (+2.75), IRWD: 14.24 (+0.41), MDCO: 38.64 (-0.05), EXEL: 9.39 (+0.24)

Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 79.66 (+2.75), PMC: 26.46 (+0.39), KEP: 27.91 (+0.11), HZNP: 19.76 (+0.33), SEM: 11.09 (+0.20)

Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 79.66 (+2.75), PGNX: 5.85 (+0.19)

Mallinckrodt plc To Report Third Quarter Fiscal 2016 Results On Aug. 2, 2016
PR Newswire - Tue Jun 21, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will report third quarter fiscal 2016 results on Tuesday, Aug. 2, 2016.
MNK: 79.66 (+2.75)

Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse
PR Newswire - Thu Jun 16, 3:45PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it will purchase and donate more than 1 million Deterra(TM) drug deactivation pouches to help combat one of the top public health threats in the U.S. today - abuse of prescription pain medications. Through this initiative, families can actively address concerns with the responsible use of pain medications and patient safety.
MNK: 79.66 (+2.75)

Mallinckrodt Submits Investigational New Drug Application for Synacthen® Depot
PR Newswire - Mon Jun 13, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced it has submitted an Investigational New Drug (IND) application for Synacthen® Depot to the U.S. Food and Drug Administration (FDA). The company will pursue an indication for the drug in treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 79.66 (+2.75)

Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus
PR Newswire - Thu Jun 09, 4:05PM CDT
Researchers for Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today presented results from the 44-week open label extension (OLE) of its company-sponsored, two-part pilot study exploring the efficacy of H.P. Acthar® Gel (repository corticotropin injection) (RCI) in Systemic Lupus Erythematosus (SLE) patients with a history of persistently active disease. Acthar is approved by the U.S. Food and Drug Administration for use during an exacerbation or as a maintenance therapy in select patients with SLE. Study data were presented at the European League Against Rheumatism (EULAR) Annual Congress in London.
MNK: 79.66 (+2.75)

Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse
PR Newswire - Mon May 23, 3:30PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it has purchased and donated 250,000 drug deactivation systems to ACT Missouri to provide patients and caregivers a secure, convenient, and environmentally safe way to dispose of unused medications.
MNK: 79.66 (+2.75)

Mallinckrodt plc to Change Fiscal Year
PR Newswire - Wed May 18, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that its Board of Directors has approved a change in the company's fiscal year end to the last Friday in December from the last Friday in September.
MNK: 79.66 (+2.75)

First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of Nephrotic Syndrome
PR Newswire - Tue May 17, 3:01PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant or treatment-intolerant idiopathic focal segmental glomerulosclerosis (FSGS). FSGS is a rare disease that can cause nephrotic syndrome, a serious kidney disorder.
MNK: 79.66 (+2.75)

The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs
Zacks Equity Research - Zacks Investment Research - Tue May 10, 10:24AM CDT
The Medicines Company (MDCO) reported a wider-than-expected loss of $1.13 per share in the first quarter of 2016.
MNK: 79.66 (+2.75), MDCO: 38.64 (-0.05), ANIP: 62.10 (+1.08), NVS: 82.40 (-0.56)

The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:30AM CDT
The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
MNK: 79.66 (+2.75), RIGP: 12.33 (+0.38), RDN: 12.73 (+0.21), OI: 18.60 (+0.37), FCAU: 6.62 (+0.54)

Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 79.66 (+2.75), ECYT: 3.08 (+0.03), SHPG: 199.17 (-3.07), NKTR: 17.53 (+0.35)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenPower Motor Company Aims for Enhanced Growth by Delisting

Updated Category News Views 218

GreenPower Motor Company Announces Delisting Decision GreenPower Motor Company Inc. (NASDAQ: GP) is making a significant move in its growth strategy. The company, which is renowned for manufacturing and distributing all-electric vehicles tailored for medium and heavy-duty applications, has decided to voluntarily delist its shares from the TSX Venture Exchange (the...

Continue Reading
VEON Announces Q4 2024 Trading Update Conference Details

Updated Category News Views 264

VEON Announces Q4 2024 Trading Update Conference Details Dubai – VEON Ltd. (NASDAQ: VEON), a prominent digital operator, has confirmed the upcoming release of significant financial information regarding its fourth quarter and full year ending December 31, 2024. This update will occur around 10:00 GST (2:00 EST) on March 20, 2025. In addition to the financial update,...

Continue Reading
Netcapital's Revenue Fraud Scandal Hits Investor Confidence

Updated Category News Views 206

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Continue Reading
Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return

Updated Category News Views 394

Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return This Memorial Day weekend marks a significant moment in history as the San Francisco East Bay welcomes back a hero after eight decades. The community prepares for a heartfelt homecoming for 2nd Lt. Thomas V. Kelly Jr., who served valiantly as a bombardier during World War II. A Journey Through History Born in...

Continue Reading
TOMY's Zoids Ultrasaurus: Gun for Nostalgia and Growth

Updated Category News Views 28

Unlocking the Power of Nostalgia with TOMY's Ultrasaurus Nostalgia isn't just an emotion; it's a powerful force that can drive sales like nobody's business, and TOMY Company knows this well. They're rolling out the big guns—literally—by adding the animated series' beloved Gravity Cannon to their new AZ-17DX Ultrasaurus model. How's that for a hook? The Gravity Cannon...

Continue Reading